NCT01698645Unknown不适用
A Spanish , Multicentre, Open-label, Observational Study to Assess Quality of Life and Satisfaction in Subjects Taking PecFent® for the Treatment of Breakthrough Cancer Pain (BTPc)
Archimedes Development Ltd1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2012年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- Satisfaction
研究概览
简要总结
National multicenter, prospective, observational study in cancer patients with chronic background pain and breakthrough pain to whom PecFent® has been prescribed under pragmatic condition by a specialist in the treatment of cancer pain conditions.
• Study objectives include assessment of early treatment satisfaction.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult (aged ≥18 years) with cancer
- •Taking at least 60 mg of oral morphine sulfate or equivalent per day for chronic background pain
排除标准
- 未提供
研究组 & 干预措施
PecFent®
干预措施: PecFent® (fentanyl) nasal spray (Drug)
结局指标
主要结局
Satisfaction
时间窗: Satisfaction will be assessed approximately 1 hour after each breakthrough pain (BTPc) episode treated with PecFent® from completion of titration through Day 7
Satisfaction will be assessed using a 4-point Likert scale.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Patient Satisfaction and Quality of Life Impact - PecFent®Breakthrough Cancer PainNCT01693328Archimedes Development Ltd300
招募中
不适用
Registry of Thrombosis & NEoplasia of "Sociedad Española de Oncología Médica"ThromboembolismCancerNCT03855592Fundación Sociedad Española de Oncologia Médica700
已完成
不适用
Chronic Non-Malignant Pain in Cancer Patients at a Supportive Care ClinicMalignant Neoplasms of Independent (Primary) Multiple SitesNCT03043378M.D. Anderson Cancer Center201
已完成
1 期
Study to Assess the Effect of Rifampicin (CYP Inducer) on Blood Levels and Safety of Olaparib in Patients With Advanced Solid TumoursSolid TumoursNCT01929603AstraZeneca32
已完成
不适用
Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2)Renal Cell CarcinomaNCT05650164Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany171